Franz Hefti

Franz Hefti is a highly experienced executive and scientist in the biotechnology and pharmaceutical industries, with a focus on neuroscience and neurodegenerative diseases.1 Here's a comprehensive overview of his career and background:

Professional Experience

Franz Hefti has held several leadership positions throughout his career:

• CEO at Prevail Therapeutics (a wholly owned subsidiary of Eli Lilly and Company) from March 2021 to present1
• Chief Development Officer at Prevail Therapeutics from September 2017 to February 20211
• COO at Proclara Biosciences Inc. from June 2014 to December 20171
• President and CEO at Acumen Pharmaceuticals Inc. from November 2011 to January 20151
• Chief Scientific Officer at Avid Radiopharmaceuticals Inc. from October 2006 to November 20111
• Executive Vice President Development at Rinat Neuroscience from 2002 to 20061
• Senior Vice President at Merck from 1995 to 20021
• Director of Neuroscience Research at Genentech from 1992 to 19951

Academic Career

Hefti has also held academic positions:

• Professor at the University of Southern California from 1989 to 19951
• Associate Professor at the University of Miami, Miller School of Medicine from 1985 to 19891

Education

• PhD in Biology from Universität Zürich (1969-1976)1
• Postdoctoral research in Neuroendocrinology at Massachusetts Institute of Technology (1977-1980)1

Expertise and Contributions

Franz Hefti has over 15 years of experience in the biotech industry as an executive, board member, co-founder, and scientific advisor for many early-stage neurology companies.2 He has published more than 250 papers on neurotrophic factors and topics in neuropharmacology.2 Since 2013, he has been a member of the Scientific Advisory Board of the Alzheimer's Disease Imaging Initiative.2

His extensive experience in neuroscience research and drug development, particularly in neurodegenerative diseases, has made him a valuable asset in the biotechnology and pharmaceutical industries.